A PLACEBO-CONTROLLED CLINICAL TRIAL WITH GABAPENTIN IN UREMIC ITCH TREATMENT

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

NOUSHAD HAMID; SADR ALDINI SH.; MOULOUDI R.; MOULAEIFARD M.; ARGANI H.; ARDALAN M.R.; ABEDI AZAR S.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Studies in Medical Sciences Year:2008 | Volume:19 | Issue:2 (SUPPLEMENT) Page(s): 29-33

Download Full-Text

Persian Verion

View:

1,951

Download:

Cites:

Information Journal Paper

Title

A PLACEBO-CONTROLLED CLINICAL TRIAL WITH GABAPENTIN IN UREMIC ITCH TREATMENT

Author(s)

Keywords

ITCHQ2

HEMODIALYSISQ3

TREATMENTQ3

GABAPENTINQ2

Abstract

Background & Aims: Prevalence of uremic ITCH is 30% in patients on dialysis, and routine TREATMENTs are often ineffective.Materials & Methods: We selected 40 HD patients and prescribed 100 mg GABAPENTIN after each HD session for 20, and prescribe placebo for the other 20 patients. Initial dose of GABAPENTIN was 100mg after every thrice-weekly HD and altered the administered dose in the base of clinical improvement. Severity of ITCHing was measured with visual analogue scale (VAS) in days 0, 2, 4, 7, 14, 21, 28, 35 after each HD session.Results: In all patients, rapid improvement in severity of ITCHing was seen and VAS was reduced to 1.5 from 7.3.Conclusion: Efficacy of GABAPENTIN was significant and side effects were acceptable for our patients and us. Therefore, GABAPENTIN is an effective and safe drug for uremic ITCH TREATMENT.

Cites

No record.

References

No record.

Cite

APA: Copy

NOUSHAD, HAMID, SADR ALDINI, SH., MOULOUDI, R., MOULAEIFARD, M., ARGANI, H., ARDALAN, M.R., & ABEDI AZAR, S.. (2008). A PLACEBO-CONTROLLED CLINICAL TRIAL WITH GABAPENTIN IN UREMIC ITCH TREATMENT. STUDIES IN MEDICAL SCIENCE (THE JOURNAL OF URMIA UNIVERSITY OF MEDICAL SCINCES), 19(2 (SUPPLEMENT)), 29-33. SID. https://sid.ir/paper/63800/en

Vancouver: Copy

NOUSHAD HAMID, SADR ALDINI SH., MOULOUDI R., MOULAEIFARD M., ARGANI H., ARDALAN M.R., ABEDI AZAR S.. A PLACEBO-CONTROLLED CLINICAL TRIAL WITH GABAPENTIN IN UREMIC ITCH TREATMENT. STUDIES IN MEDICAL SCIENCE (THE JOURNAL OF URMIA UNIVERSITY OF MEDICAL SCINCES)[Internet]. 2008;19(2 (SUPPLEMENT)):29-33. Available from: https://sid.ir/paper/63800/en

IEEE: Copy

HAMID NOUSHAD, SH. SADR ALDINI, R. MOULOUDI, M. MOULAEIFARD, H. ARGANI, M.R. ARDALAN, and S. ABEDI AZAR, “A PLACEBO-CONTROLLED CLINICAL TRIAL WITH GABAPENTIN IN UREMIC ITCH TREATMENT,” STUDIES IN MEDICAL SCIENCE (THE JOURNAL OF URMIA UNIVERSITY OF MEDICAL SCINCES), vol. 19, no. 2 (SUPPLEMENT), pp. 29–33, 2008, [Online]. Available: https://sid.ir/paper/63800/en

Related Journal Papers